Regdanvimab vs placebo
Clinical progression: development of severe symptoms (≥ 7 WHO scale, IMV) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 1 participantsLow